# OnCo record nct06363994 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06363994/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06363994", "NCT06363994" ;
  schema:name "A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL"@en ;
  schema:description "A phase 3 trial of Orelabrutinib, Bendamustine, Rituximab in mantle cell lymphoma, run by InnoCare Pharma Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06363994/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06363994> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-05-29" ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/orelabrutinib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/innocare/> .